amylin vs glp 1 Amycretin: The Oral Obesity Pill That Could Change Everything About Access to Metabolic Medicine The direct physiologic effects of – Identification and utility exploration of

Oral GLP-1 options, next-generation compounds targeting different pathways, and eventually generic versions of current products will create new pricing leverage

P = 0.06) ( The reported CV benefits were not associated with an increase in risk of severe hypoglycemia, retinopathy, or pancreatic adverse effects ( Moreover, a very recent multicenter, double-blind, randomized, placebo-controlled trial (the SELECT trial), showed that weekly 2.4 mg subcutaneous semaglutide was superior to placebo in reducing the risk of CV death, nonfatal MI, or nonfatal stroke at a mean follow-up of 39.8 months

#GLP1 #ObesityCare #PharmaCommercial #PatientPersistence #DigitalHealth #MarketAccess Eli Lilly and Company Novo Nordisk Pfizer Amgen Sanofi To view or add a comment, sign in What you're doing is working

Focus on a solid foundation of nutrition, training, and recovery, and use supplements like L-carnitine as the cherry on top not the whole cake

A clean rule of thumb: Pick a water volume that makes your typical measurement land on a round number of units